FINANCING
Who is raising money: selling new shares, filing room to sell more later, or borrowing. New shares give every holder a smaller slice.
Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing
Key
Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing
Newest first. A company with several filings is one row; open it for each.
- HRTXHeron Therapeutics, Inc.Convertible notes$35.0M73% of value−13.8%8-K ↗
- AVIRAtea Pharmaceuticals, Inc.Notes$200.0M63% of value−8.1%8-K ↗
- ABEOAbeona Therapeutics Inc.Private placement, 3.20M shares$30.0M18% of value−42.0%8-K ↗
- VBIOValion Bio, Inc.Private placement, 22K shares$700K68% of value−5.7%8-K ↗
- INTTInTest CorporationShelf$100.0M−18.2%S-3 ↗
- GPUSHyperscale Data, Inc.Convertible notes$16.2M48% of value−7.8%424B5 ↗
- DFNST3 Defense Inc.Unregistered sale of shares, 8-K item 3.02size not available−39.8%8-K ↗
- CETYClean Energy Technologies, Inc.Unregistered sale of shares, 8-K item 3.02size not available+1.8%8-K ↗
- AUUDAuddia Inc.Unregistered sale of shares, 8-K item 3.02size not available−64.0%8-K ↗
- RENXRenX Enterprises Corp.Unregistered sale of shares, 8-K item 3.02size not available−20.4%8-K ↗
- FFAIFaraday Future Intelligent Electric Inc.Unregistered sale of shares, 8-K item 3.02size not available−65.9%8-K ↗
- EXOZeXoZymes, Inc.Registration for an offeringsize not available−34.0%S-1 ↗
- OBIOOrchestra BioMed Holdings, Inc.Public offering, 15.0M shares at $5.00$75.0M15% of value+15.8%424B5 ↗
- BIVIBioVie Inc.Registered direct offering, 4.00M shares at $1.60size not available−39.8%8-K ↗
- SILOSilo Pharma, Inc.Private placement, 861K shares at $1.50size not available+28.6%8-K ↗
- GOGOGogo Inc.Notes$33.4M9.8% of value−35.6%8-K ↗
- USGOU.S. GoldMining Inc.At-the-market programme$3.2M6.0% of value−30.2%424B5 ↗
- HITHealth In Tech, Inc.Notes$3.0M9.8% of value−31.3%8-K ↗
- GNLGlobal Net Lease, Inc.At-the-market programme, with BofA Securities$300.0M22% of value−12.4%424B5 ↗
- NAASNaaS Technology Inc.Shelfsize not available−23.1%F-3 ↗
- NXTSNexentis Technologies Inc.Reverse split, 1-for-5−38.5%8-K ↗
- INOInovio Pharmaceuticals, Inc.Public offering, 71.4M shares at $1.05$75.0M23% of value+44.9%424B5 ↗
- ZBIOZenas BioPharma, Inc.At-the-market programme, with Jefferies$200.0M12% of value−15.6%424B5 ↗
- EDBLEdible Garden AG IncorporatedUnregistered sale of shares, 8-K item 3.02size not available−38.1%8-K ↗
- NXXTNextNRG, Inc.Unregistered sale of shares, 8-K item 3.02size not available−65.0%8-K ↗
- ATYRaTyr Pharma, Inc.At-the-market programme, with Jefferies$80.0M−39.8%424B5 ↗
- NTCLNetClass Technology IncPublic offering, 3.00M sharessize not available−46.6%424B5 ↗
- SXTP60 Degrees Pharmaceuticals, Inc.Unregistered sale of shares, 8-K item 3.02size not available−48.9%8-K ↗
- AXGSolowin HoldingsPublic offeringsize not available−45.5%424B5 ↗
- EVTCEVERTEC, Inc.Notes$100.0M5.7% of value−12.3%8-K ↗
- DTILPrecision BioSciences, Inc.Public offering, 16.1M shares at $7.75$125.0M44% of value−25.0%424B5 ↗
- FDUSFidus Investment CorporationAt-the-market programme, with Raymond James & Associates$400.0M55% of value−6.6%424B3 ↗
- VSTMVerastem, Inc.At-the-market programme, with Cantor Fitzgerald$100.0M13% of value−32.5%S-3ASR ↗
- VSTMVerastem, Inc.Shelf, automatic (S-3ASR)no dollar limit−32.5%S-3ASR ↗
- ANVSAnnovis Bio, Inc.Public offering, 21.0M shares at $1.00$21.0M48% of value+6.3%424B5 ↗
- ANIPANI Pharmaceuticals, Inc.Notes$676.0M43% of value−1.5%8-K ↗
- BNGOBionano Genomics, Inc.Public offering, 661K sharessize not available−25.3%424B3 ↗
- CHGAChange Agents CorporationUnregistered sale of shares, 8-K item 3.02size not available−16.8%8-K ↗
- ISPCiSpecimen Inc.Unregistered sale of shares, 8-K item 3.02size not available−43.5%8-K ↗
- RZLTRezolute, Inc.Shelf$400.0M+7.7%S-3 ↗
- ASPNAspen Aerogels, Inc.Shelf$150.0M−13.4%S-3 ↗
- SUNSSunrise Realty Trust, Inc.Unregistered sale of shares, 8-K item 3.02size not available−4.0%8-K ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−50.3%S-3 ↗
- FATEFate Therapeutics, Inc.Shelf$300.0M−50.3%S-3 ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−50.3%424B5 ↗
- LOBLive Oak Bancshares, Inc.Public offering$100.0M6.8% of value−6.4%424B5 ↗